Dishman Carbogen Amcis Ltd (NSE: DCAL, BSE: 540701) is a Ahmedabad, Gujarat-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹2,349 Cr, it ranks #1,160 by market cap among the 6,137 Indian listed companies on FinBizNet, and #10 of 11 in Pharmaceutical CDMO and CRO Services. At ₹136.28 (as of 25 Oct 2026), the share price is 55.0% below its 52-week high of ₹303.00 and 6.1% above its 52-week low of ₹128.50. The share price is down 52.5% over one year and down 25.8% over three months.
| Current Price | ₹136.28 |
|---|---|
| Market Cap | ₹2,349 Cr |
| NSE Symbol | DCAL |
| BSE Code | 540701 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 23.5 |
| Return on Equity | 1.56% |
| Return on Assets | 1.34% |
| 52-Week Range | ₹128.50 – ₹303.00 |
| 1-Year Price Change | -52.5% |
| 3-Month Price Change | -25.8% |
| Beta (1Y) | 0.48 |
| Dividend Yield | 0.00% |
| Headquarters | Ahmedabad, Gujarat |
| Website | imdcal.com |
| Revenue | ₹678 Cr |
|---|---|
| Net Profit | ₹-58 Cr |
| Net Margin | -8.5% |
| EPS (Basic) | ₹-3.69 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
1. Contract Research and Manufacturing Services (CRAMS)-This segment provides pharmaceutical contract research and manufacturing services. 2. Vitamin-D, Bulk Drugs, Quats, Speciality Chemicals and Traded Goods-This segment manufactures and distributes vitamin D analogues, cholesterol, bulk drugs, intermediates, and quats and specialty chemicals. 3. Unallocated/Others-0 4. Segment Adjustment-0
1. Medical Labs & Research-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Dishman Carbogen Amcis Ltd | ₹2,349 Cr | 23.5 | 1.56% | ₹678 Cr | -52.5% |
Listed by market capitalisation. Ratios are shown for context only.
Dishman Carbogen Amcis Ltd is trading at ₹136.28, with a market capitalisation of ₹2,349 Cr.
Dishman Carbogen Amcis Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Dishman Carbogen Amcis Ltd has a P/E of 23.5 and a return on equity of 1.56%.
Dishman Carbogen Amcis Ltd is listed on the NSE under the symbol DCAL and on the BSE under the scrip code 540701.
Dishman Carbogen Amcis Ltd's share price is down 52.5% over one year and down 25.8% over three months. Its 52-week range is ₹128.50 to ₹303.00.
In Q1 FY27, Dishman Carbogen Amcis Ltd reported revenue of ₹678 Cr and net profit of ₹-58 Cr, with basic EPS of ₹-3.69 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.